Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
NCT00543010 · Merck Sharp & Dohme LLC · PHASE3 · terminated · last registry update 2015-06-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-06-01Phase 3 first posted: Sanofi, Insulin glargine/lixisenatide fixed ratio combination + liraglutide (NCT02787551)
- 2016-05-11Phase 3 first posted: Xijing Hospital of Digestive Diseases, Mesalazine Sustained-Release Tablets + Riboflavin Sodium Phosphate Injection (NCT02769494)
- 2016-03-25Results posted on the registry: Merck Sharp & Dohme LLC, MK-4074 200 mg + Placebo for MK-4074 (NCT01431521)
- 2016-01-28Phase 3 first posted: Centre Hospitalier Universitaire de Saint Etienne, 5-ASA + Corticosteroids (NCT02665845)
- 2016-01-15Phase 3 first posted: Biogen, Placebo capsules + Bardoxolone methyl capsules (NCT02657356)
- 2015-11-20Results posted on the registry: Novo Nordisk A/S, insulin degludec/insulin aspart + biphasic insulin aspart 30 (NCT01009580)
- 2015-10-29Results posted on the registry: Merck Sharp & Dohme LLC, Omarigliptin + Placebo to omarigliptin (NCT01217073)
- 2015-10-29Results posted on the registry: Merck Sharp & Dohme LLC, Omarigliptin + Matching placebo to omarigliptin (NCT01697592)
- 2015-10-22Phase 3 first posted: Sanofi, Alirocumab + Placebo (NCT02584504)
- 2015-09-14Phase 3 first posted: University of Guadalajara, Berberine + Bezafibrate (NCT02548832)
- 2015-08-13Phase 3 first posted: Ferring Pharmaceuticals, Mesalamine + Placebo (NCT02522780)
- 2015-08-13Phase 3 first posted: Ferring Pharmaceuticals, Mesalamine + Placebo (NCT02522767)
- 2015-07-09Results posted on the registry: Shire, MMX Mesalamine + MMX Mesalamine (NCT01130844)
- 2015-04-20Results posted on the registry: Shire, Mesalamine (NCT02125292)
- 2015-03-17Results posted on the registry: Pusan National University Hospital, vildagliptin + Pioglitazone (NCT01882907)
- 2014-12-19Results posted on the registry: Wake Forest University Health Sciences, Pioglitazone + Placebo (NCT00315146)
- 2014-11-06Phase 3 first posted: Takeda, Pioglitazone + Placebo (NCT02284906)
- 2014-10-31Phase 3 first posted: Dr. Falk Pharma GmbH, LT-02 + Placebo (NCT02280629)
- 2014-10-28Phase 3 first posted: Schneider Children's Medical Center, Israel, Placebo (NCT02277223)
- 2014-08-15Results posted on the registry: Annette Langseder, Asacol (NCT00349388)
- 2014-08-01Results posted on the registry: Bausch Health Americas, Inc., budesonide-MMX® 6 mg + budesonide-MMX® 9 mg (NCT00679432)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision